Previous 10 | Next 10 |
NEW YORK and LONDON, June 28, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced ...
Akari Therapeutics (NASDAQ: AKTX ) reports positive results for Part A of TRACKER, a Phase I/II clinical trial evaluating the safety and efficacy of topical nomacopan in moderate to severe atopic keratoconjunctivitis (AKC). More news on: Akari Therapeutics, Plc, Healthcare stocks news, S...
Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. Improvement in mean composite clinical efficacy score of 35% by Day 14 and 55% by Day 56. All patients were on maximal dosage of cyclosporin...
Akari Therapeutics (NASDAQ: AKTX ): Q1 GAAP EPS of $0.00 beats by $0.05 . More news on: Akari Therapeutics, Plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trials Further clinical data from BP and AKC trials anticipated in 2019 Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombot...
- Biotech and healthcare stocks are loved by traders for their big price moves, which can happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and r...
In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants administered intravitreally, reported: ○ Significant improvement in clinical scoring versus control ɜ...
Akari Therapeutics ( AKTX ) announced that it had achieved positive results from its phase 2 study using its drug Nomacopan (Coversin) to treat patients with bullous pemphigoid ((BP)). This could provide patients with a new treatment option other than current drugs that cause adverse eve...
Arrowhead Pharmaceuticals ( ARWR ) - The company announced that dosing has begun in a new triple combination cohort utilizing JNJ-3989 plus additional undisclosed agents in the ongoing phase 1/2 study in patients with chronic hepatitis B virus. As a result of opening this new cohort, Arrowhe...
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease Area Index (BPDAI) score and blistering in ongoing Phase II clinical trial Pivotal clinical trial for pediat...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies...